Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Theravance Biopharma, Inc. (TBPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.14+0.03 (+0.30%)
At close: 04:00PM EDT
10.14 0.00 (0.00%)
After hours: 04:14PM EDT
Advertisement

Theravance Biopharma, Inc.

Ugland House
South Church Street PO Box 309
George Town KY1-1104
Cayman Islands

https://www.theravance.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees158

Key Executives

NameTitlePayExercisedYear Born
Mr. Rick E. Winningham M.B.A.Chairman & CEO1.05MN/A1960
Mr. Andrew Asa Hindman M.B.ASr. VP & CFO575.39kN/A1973
Ms. Rhonda F. FarnumChief Bus. Officer and Sr. VP of Commercial & Medical Affairs435.52kN/A1965
Dr. Richard A. Graham Ph.D.Sr. VP of R&D469.44kN/A1974
Ms. Gail B. CohenVP of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Brett A. Grimaud Esq.Sr. VP, Gen. Counsel & Sec.N/AN/AN/A
Ms. Stacy L. PryceSr. VP & Chief Strategy OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Corporate Governance

Theravance Biopharma, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement